6/12/2006 12:32:36 PM ET


    SWISS MEDICA RECEIVES FDA CERTIFICATES OF FREE SALE FOR O24™ THAT ALLOW FOR
    INTERNATIONAL DISTRIBUTION
      
    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB: SWME
    June 12, 2006

    Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) announced today that the company has received
    Certificates of Free Sale from the US Food and Drug Administration (“FDA”) for its patented O24™ Pain
    Neutralizer and O24 Fibromyalgia™ products.

    This issuance of these certificates by the FDA confirms that Swiss Medica’s O24™ Pain Neutralizer and O24
    Fibromyalgia™ products meet all the standards necessary for international export. Certificates of Free Sale
    confirm to foreign governments that the products meet or exceed all the standards necessary for them to be
    marketed in the United States, and meet specific US manufacturing regulations such as cGMP (current Good
    Manufacturing Practice). Many countries required these certificates prior to allowing importation of U.S.
    manufactured healthcare products like O24™.

    O24™ Pain Neutralizer was launched nationally in the United States by Swiss Medica in 2005 and is available in
    the pain relief section of leading pharmacies throughout North America. The topical pain reliever and anti-
    inflammatory is a patented, medically/clinically tested, all natural product formulated with seven essential oils and
    no chemical binders. It has being used by and recommended by leading healthcare professionals including
    Medical Doctors and Doctors of Osteopathy. In addition, athletes from many sports including football, hockey,
    boxing and skiing like O24™ for its quick pain relief and non-doping ingredients.

    O24 Fibromyalgia™ was launched in late 2005 and is the first patented, clinically tested and non-prescription
    product specifically for patients to fight the intense, debilitating pain caused by Fibromyalgia. The product was
    awarded the first ever Seal of Approval from the U.S. National Fibromyalgia Association (NFA).

    O24™ has been medically and clinically tested and details of those trials are available at
    www.O24zone.com/clinical..html

    Swiss Medica's President and Chief Operating Officer, Grant Johnson stated “The FDA’s issuance of these
    certificates is coming at a perfect time. International interest in our products is growing quickly because of the
    science behind our products and the extraordinary efficacy of O24™ for most people with pain.”

    About Swiss Medica, Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be
    a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

    Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
    relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
    healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
    throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
    www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

    Swiss Medica launched the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1) over-the-
    counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently
    awarded O24 Fibromyalgia™ their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the
    long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of
    the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
    who used the placebo. Customers can visit www.O24zone.com for information on O24 Fibromyalgia™ and to
    order the product online.

    Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
    Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
    changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
    www.pmsescape.com for additional information and ordering details.

    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
    United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    For more information, please contact: